6 research outputs found

    Les trois temps de la prise en charge oncogénétique : la consultation, l’analyse en laboratoire et le suivi personnalisé

    Full text link
    International audienceIt is paramount to identify patients whose cancer is associated with genetic susceptibility to the disease, since their long-term management depends on it. Anatomical and molecular pathologists play a key role in the process. Indeed, their diagnosis supports or even sometimes warrants germline genetic testing. For example, a colorectal cancer with mismatch repair protein expression loss suggests Lynch syndrome, while a rare type of renal cell carcinoma with fumarate hydratase expression loss is highly evocative of hereditary leiomyomatosis and renal cell carcinoma syndrome. Similarly, the presence of the T790M EGFR variant before treatment in a non-small cell lung carcinoma warrants further testing as the variant is likely of germline origin. Patients with suspected genetic susceptibility to cancer are referred to the nearest clinical cancer genetics clinic. The cancer geneticist, assisted by a genetic counselor, then collects detailed personal and familial information, sometimes feeds them into bioinformatics tools or clinico-pathological scores, decides whether germline genetic analysis is justified, determines which genes should be analysed, and prescribes testing. Germline testing is carried out on a blood sample by expert laboratories using next generation sequencing on panels of cancer susceptibility genes. The cancer geneticists then returns the result to the patient. When a pathogenic variant is identified, the patient’s management ismodified, with recommendations ranging from intensified surveillance to risk-reducing surgery. Treatment is sometimes adapted to the pathogenic variant. In addition, relatives can undergo genetic testing, should they wish to know whether they carry the familial variant. In the near future, we expect clinical cancer genetics to move towards strengthened partnerships with molecular pathologists and medical oncologists. Somatic genetic analyses are now routine, at least in metastatic cancer, and a proportion of the tumoral variants identified are actually of germline origin. As for the oncologists, the development of mainstreaming programs where they are allowed to prescribe germline testing under the supervision of a cancer genetics team is unavoidable.Les patients dont le cancer est associé à une prédisposition génétique doivent être identifiés, puisque leur prise en charge à long terme en dépend. Les anatomopathologistes jouent un rôle clé dans l’initiation de cette démarche. En effet, un diagnostic précis oriente les investigations oncogénétiques, voire les justifie s’il s’agit par exemple d’un cancer colorectal avec perte d’expression de protéines codées par les gènes de mésappariements de l’ADN ou d’un type rare de cancer du rein perdant l’expression de la fumarate hydratase. Les analyses génétiques tumorales représentent aussi une porte d’entrée pour l’Oncogénétique, par exemple cancer bronchopulmonaire avec variant tumoral EGFR T790M pré-traitement. En cas de suspicion de prédisposition génétique, le patient est adressé en consultation d’Oncogénétique. Le médecin accompagné d’un conseiller en génétique y collecte les informations personnelles et familiales, les intègre à un processus décisionnel impliquant des outils bioinformatiques et des scores clinico- pathologiques, et prescrit les analyses constitutionnelles. Le laboratoire d’Oncogénétique réalise ensuite l’analyse sous forme de panel de gènes avec des machines de séquençage haut débit. Le résultat est rendu quelques semaines plus tard par l’Oncogénéticien. L’observation d’un variant pathogène résulte en des recommandations de prise en charge à long terme, dépistage et chirurgie de réduction de risque. Les avancées de la médecine permettent aussi dorénavant d’adapter parfois les traitements au résultat. En outre, l’identification d’un variant pathogène permet ensuite aux apparentés de bénéficier de tests génétiques. L’évolution à court terme de l’Oncogénétique se caractérisera par un partenariat renforcé avec les anatomopathologistes et pathologistes moléculaires, puisque la généralisation des analyses génétiques tumorales à visée thérapeutique révèlera de manière incidentale des variants pathogènes constitutionnels. Par ailleurs la mise en place de circuits de « mainstreaming » avec les oncologues, dans lesquels ces derniers prescrivent des analyses constitutionnelles dans un cadre précis et sous la supervision d’un Oncogénéticien, est inéluctable

    Caecal microbiota compositions from 7-day-old chicks reared in high-performance and low-performance industrial farms and systematic culturomics to select strains with anti-Campylobacter activity.

    Full text link
    There is growing interest in exploring the chickens' intestinal microbiota and understanding its interactions with the host. The objective is to optimize this parameter in order to increase the productivity of farm animals. With the goal to isolate candidate probiotic strains, specific culturomic methods were used in our study to culture commensal bacteria from 7-days old chicks raised in two farms presenting long history of high performance. A total of 347 isolates were cultured, corresponding to at least 64 species. Among the isolates affiliated to the Firmicutes, 26 had less than 97% identity of their partial 16S sequence with that of the closest described species, while one presented less than 93% identity, thus revealing a significant potential for new species in this ecosystem. In parallel, and in order to better understand the differences between the microbiota of high-performing and low-performing animals, caecal contents of animals collected from these two farms and from a third farm with long history of low performance were collected and sequenced. This compositional analysis revealed an enrichment of Faecalibacterium-and Campylobacter-related sequences in lower-performing animals whereas there was a higher abundance of enterobacteria-related sequences in high-performing animals. We then investigated antibiosis activity against C. jejuni ATCC 700819 and C. jejuni field isolate as a first phenotypic trait to select probiotic candidates. Antibiosis was found to be limited to a few strains, including several lactic acid bacteria, a strain of Bacillus horneckiae and a strain of Escherichia coli. The antagonist activity depended on test conditions that mimicked the evolution of the intestinal environment of the chicken during its lifetime, i.e. temperature (37°C or 42°C) and oxygen levels (aerobic or anaerobic conditions). This should be taken into account according to the stage of development of the animal at which administration of the active strain is envisaged
    corecore